SunTrust is captivated by BABA’s powerhouse core retail; Baird deems PYPL cream of the e-commerce crop.
Canaccord’s Matt Ramsay is bullish in his 3Q preview of AMD, but continues to be apprehensive on INTC.
Jeff Van Sinderen believes that SKX shareholders’ best days are ahead.
Healthcare analysts take different approaches to valuing Transenterix and Valeant.
Hartaj Singh believes QURE trots out an upper hand advantage with AMT-061.
Notably, AAPL has reduced projections even during some of the greatest iPhone cycles, says Brian White.
Anthony Chukumba says Price had bad history, and Amazon could use a fresh revamp in Hollywood’s eyes.
Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
Louise Chen anticipates more generic pricing pressure hit 3Q earnings for generic manufacturers.
Youssef Squali believes strong monetization and user growth have treated FB well during the quarter.